121 related articles for article (PubMed ID: 30619084)
1. Influence of the
Gao M; Zhu B; Li P; Zhang G; Chen K; Lv H; Ma R; Zhang L; Fan Y; Kang X
Front Endocrinol (Lausanne); 2018; 9():751. PubMed ID: 30619084
[No Abstract] [Full Text] [Related]
2. Association between acromegaly and a single nucleotide polymorphism (rs2854744) in the IGFBP3 gene.
Gao M; Zhu B; Xu Z; Liu S; Liu J; Zhang G; Gao Y; Fan Y; Kang X
BMC Med Genet; 2018 Oct; 19(1):182. PubMed ID: 30290787
[TBL] [Abstract][Full Text] [Related]
3. Analysis of IGF(CA)19 and IGFBP3-202A/C gene polymorphisms in patients with acromegaly: association with clinical presentation and response to treatments.
Ramos-Leví AM; Marazuela M; Paniagua A; Quinteiro C; Riveiro J; Álvarez-Escolá C; Lúcas T; Blanco C; de Miguel P; Martínez de Icaya P; Pavón I; Bernabeu I
Eur J Endocrinol; 2015 Feb; 172(2):115-22. PubMed ID: 25385818
[TBL] [Abstract][Full Text] [Related]
4. Influence of growth hormone receptor (GHR) exon 3 and -202A/C IGFBP-3 genetic polymorphisms on clinical and biochemical features and therapeutic outcome of patients with acromegaly.
Jallad RS; Trarbach EB; Duarte FH; Jorge AA; Bronstein MD
Pituitary; 2015 Oct; 18(5):666-73. PubMed ID: 25552351
[TBL] [Abstract][Full Text] [Related]
5. Association between ACE and AGT polymorphism and cardiovascular risk in acromegalic patients.
Erbas T; Cinar N; Dagdelen S; Gedik A; Yorgun H; Canpolat U; Kabakci G; Alikasifoglu M
Pituitary; 2017 Oct; 20(5):569-577. PubMed ID: 28712073
[TBL] [Abstract][Full Text] [Related]
6. Polymorphism in IGFBP3 gene is associated with prostate cancer risk: an updated meta-analysis.
Qie Y; Nian X; Liu X; Hu H; Zhang C; Xie L; Han R; Wu C; Xu Y
Onco Targets Ther; 2016; 9():4163-71. PubMed ID: 27462171
[TBL] [Abstract][Full Text] [Related]
7. Associations of insulin-like growth factor binding protein-3 gene polymorphisms with IGF-I activity and lipid parameters in adolescents.
Mong JL; Ng MC; Guldan GS; Tam CH; Lee HM; Ma RC; So WY; Wong GW; Kong AP; Chan JC; Waye MM
Int J Obes (Lond); 2009 Dec; 33(12):1446-53. PubMed ID: 19786971
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of disease activity by IGF-I and IGF binding protein-3 (IGFBP3) in acromegaly patients distributed according to a clinical score.
Jasper H; Pennisi P; Vitale M; Mella A; Ropelato G; Chervin A
J Endocrinol Invest; 1999 Jan; 22(1):29-34. PubMed ID: 10090134
[TBL] [Abstract][Full Text] [Related]
9. The -202 A allele of insulin-like growth factor binding protein-3 (IGFBP3) promoter polymorphism is associated with higher IGFBP-3 serum levels and better growth response to growth hormone treatment in patients with severe growth hormone deficiency.
Costalonga EF; Antonini SR; Guerra-Junior G; Mendonca BB; Arnhold IJ; Jorge AA
J Clin Endocrinol Metab; 2009 Feb; 94(2):588-95. PubMed ID: 18984657
[TBL] [Abstract][Full Text] [Related]
10. Role of IGF1-(CA)19 promoter microsatellite in the clinical presentation of acromegaly.
Sala E; Filopanti M; Ferrante E; Barbieri AM; Malchiodi E; Verrua E; Giavoli C; Lania AG; Arosio M; Beck-Peccoz P; Spada A; Mantovani G
Eur J Clin Invest; 2014 Dec; 44(12):1222-9. PubMed ID: 25370837
[TBL] [Abstract][Full Text] [Related]
11. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
[TBL] [Abstract][Full Text] [Related]
12. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.
Bianchi A; Giustina A; Cimino V; Pola R; Angelini F; Pontecorvi A; De Marinis L
J Clin Endocrinol Metab; 2009 Jun; 94(6):2015-22. PubMed ID: 19336510
[TBL] [Abstract][Full Text] [Related]
13. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
[TBL] [Abstract][Full Text] [Related]
14. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
[TBL] [Abstract][Full Text] [Related]
15. d3-Growth hormone receptor polymorphism in acromegaly: effects on metabolic phenotype.
Montefusco L; Filopanti M; Ronchi CL; Olgiati L; La-Porta C; Losa M; Epaminonda P; Coletti F; Beck-Peccoz P; Spada A; Lania AG; Arosio M
Clin Endocrinol (Oxf); 2010 May; 72(5):661-7. PubMed ID: 20447065
[TBL] [Abstract][Full Text] [Related]
16. Acromegaly.
Scacchi M; Cavagnini F
Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
[TBL] [Abstract][Full Text] [Related]
17. Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values?
Kohler S; Tschopp O; Sze L; Neidert M; Bernays RL; Spanaus KS; Wiesli P; Schmid C
Gen Comp Endocrinol; 2013 Jul; 188():282-7. PubMed ID: 23648743
[TBL] [Abstract][Full Text] [Related]
18. Serum leptin levels and GHR-d3/fl gene polymorphism in acromegalic patients with thyroid nodules.
Topsakal S; Akin F; Turgut S; Yerlikaya E; Yaylali GF
Adv Clin Exp Med; 2017; 26(2):281-286. PubMed ID: 28791847
[TBL] [Abstract][Full Text] [Related]
19. Impact of the IGFBP3 A-202C polymorphism on susceptibility and clinicopathologic features of breast cancer.
Ma X; Kang H; Dai Z; Ma L; Jin Y; Wang X
Biomed Pharmacother; 2015 Apr; 71():108-11. PubMed ID: 25960224
[TBL] [Abstract][Full Text] [Related]
20. The interactive effect of GHR-exon 3 and -202 A/C IGFBP3 polymorphisms on rhGH responsiveness and treatment outcomes in patients with Turner syndrome.
Braz AF; Costalonga EF; Montenegro LR; Trarbach EB; Antonini SR; Malaquias AC; Ramos ES; Mendonca BB; Arnhold IJ; Jorge AA
J Clin Endocrinol Metab; 2012 Apr; 97(4):E671-7. PubMed ID: 22278433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
